Monday, November 29

Everything you need to know about the Spanish vaccine against covid

Everything you need to know about the Spanish vaccine against covid

Everything you need to know about the Spanish vaccine against covid

The Spanish Agency for Medicines and Health Products (AEMPS) has authorized the clinical trial of the spanish vaccine PHH-1V against covid. It is the first antidote developed in our country that receives the approval of this organism to be tested in humans.

This week, the Josep Trueta Hospital in Girona and the Hospital Clinic in Barcelona have begun screening to select the volunteers who will receive the HIPRA PHH-1V vaccine. This test will determine the effectiveness of this vaccine with 100% Spanish stamp

It may interest you: Herpes Zoster, the other effect of the covid vaccine

Those chosen to participate in the phase I / IIa clinical trial must be between 18 and 39 years old, have not contracted the disease or have been vaccinated.

The Spanish vaccine, easy to preserve

The Spanish HIPRA Covid-19 vaccine, developed by the HIPRA laboratory, is a recombinant protein antidote to optimize safety and “achieve a virus-neutralizing immune response.”

The preservation of the vaccine is between 2 and 8º C, which facilitate logistics and distribution Of the same. It would be one of the easiest to store alongside those of Janssen and AstraZeneca.

The vacuna Johnson & Johnson It is kept for up to three months between 2 and 8º C, like the one developed by Oxford, although the latter cannot be frozen.

On the other side of the coin, Pfizer and Moderna, which are the most complex to save.

The BioNTech vaccine must be stored at a temperature between -80 and -60º C, so a series of measures must be taken for a correct distribution. In the case of Spikevax (Moderna) it can be stored for up to 6 months at -20º C.

The Spanish vaccine protects against new variants

According to Spanish Agency for Medicines and Health Products notes that this vaccine is based on two structurally similar recombinant proteins. One corresponds to the alpha variant and the other to the beta variant. These two proteins unite to form “a unique structure called a dimer, which are accompanied by an adjuvant that increases the immune response”.

When would the manufacture of the Spanish vaccine begin?

In this I / IIa clinical trial, volunteers will receive low doses. If no safety problem is detected after the evaluation, the subsequent doses will be increased. Each participant will receive 2 immunizations 21 days apart, as with the Pfizer / BioNTech vaccine.

An independent watchdog committee will study the data resulting from this phase and, only if regulatory standards are met, will the vaccine be authorized for commercialization.

The company’s forecast is that the production of the vaccine will start in October at the HIPRA facilities. The goal is for commercialization to start in early 2022.

The clinical trials are expected to be completed successfully to start production in October of this year, with the aim of launching its commercialization by the end of 2021, subject to obtaining the appropriate authorizations. Based on current HIPRA projections, there are expected to be 400 million doses during the year 2022 ″, says the company.

However, by 2023, HIPRA emphasizes, Spanish vaccine production it could triple to 1,200 million doses.

What is HIPRA?

According to the laboratory on its website, HIPRA ranks 6th in the ranking of vaccines for mental health. “It is the laboratory that has launched the most innovative and technological vaccines in the last 10 years, with a total of 22 vaccines,” he said in a statement.

In addition, the Catalan multinational dedicates 10% of its annual turnover to research and development of new vaccines.

Leave a Reply

Your email address will not be published. Required fields are marked *